These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5170858)

  • 1. Some thoughts on the generic equivalency debate.
    Berry FB
    Med Times; 1971 Sep; 99(9):199-201. PubMed ID: 5170858
    [No Abstract]   [Full Text] [Related]  

  • 2. The integrity of generic drugs.
    Fisher DW
    Hosp Pract (Off Ed); 1989 Sep; 24(9):9. PubMed ID: 2504753
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic bioequivalence: a scientific consensus needed.
    Am Fam Physician; 1987 Feb; 35(2):91, 95. PubMed ID: 3812175
    [No Abstract]   [Full Text] [Related]  

  • 4. Generic vs. brand name drugs--defining and enforcing standards.
    Lasagna LC
    Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827
    [No Abstract]   [Full Text] [Related]  

  • 5. Biopharmaceutic equivalency and the role of the Food & Drug Administration.
    Hodges RM
    Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859
    [No Abstract]   [Full Text] [Related]  

  • 6. Benefits and liabilities of generic prescribing.
    Lee AM
    W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384
    [No Abstract]   [Full Text] [Related]  

  • 7. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining drug equality.
    Hecht A
    FDA Consum; 1975 Nov; 9(9):18-20. PubMed ID: 10316633
    [No Abstract]   [Full Text] [Related]  

  • 9. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation.
    Daemmrich A
    Pharm Hist; 2007; 49(2):61-75. PubMed ID: 18368740
    [No Abstract]   [Full Text] [Related]  

  • 10. How good are our drugs?
    Miller LC
    Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
    [No Abstract]   [Full Text] [Related]  

  • 11. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs: the AMA and FDA roles.
    Appel JZ
    J Ark Med Soc; 1966 Jul; 63(2):67-9. PubMed ID: 4223555
    [No Abstract]   [Full Text] [Related]  

  • 13. New drugs: the AMA and the FDA.
    Appel JZ
    Ann Allergy; 1966 Jul; 24(7):333-6. PubMed ID: 5941864
    [No Abstract]   [Full Text] [Related]  

  • 14. Striving for standards in bioequivalence assessment: a review.
    Schulz HU; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Aug; 29(8):293-8. PubMed ID: 1743802
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug names--a semblance of order.
    Feldman EG
    J Pharm Sci; 1966 Jun; 55(6):i. PubMed ID: 5924136
    [No Abstract]   [Full Text] [Related]  

  • 16. ADA, FDA guard quality, safety.
    Dent Stud; 1975 Mar; 53(6):25, 55. PubMed ID: 1055065
    [No Abstract]   [Full Text] [Related]  

  • 17. Major events during the generic drug investigations.
    Am Pharm; 1990 Jul; NS30(7):38-9. PubMed ID: 2363392
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA reiterates warning against online drug buying.
    Rados C
    FDA Consum; 2004; 38(5):17. PubMed ID: 15595143
    [No Abstract]   [Full Text] [Related]  

  • 19. Generic equivalency: does it exist?
    Payne RJ
    Med Ann Dist Columbia; 1969 Sep; 38(9):490-2. PubMed ID: 5259629
    [No Abstract]   [Full Text] [Related]  

  • 20. Achieving a quality drug supply.
    Nelson G
    J Am Pharm Assoc; 1974 Oct; 14(10):548-9, 564. PubMed ID: 4420394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.